Fiche société
Allife Medical Science and Technology Co., Ltd.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Anti-CD19 iCAR NK CellsThis is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 iCAR NK cells in patients with relapsed refractory B cell lymphoma. | SEP | Phase 1 | Immunomodulation | À vérifier | |
| Anti-CD19 iCAR NK CellsThis is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 iCAR NK cells in patients with relapsed refractory B cell lymphoma. | SEP | Phase 1 | Immunomodulation | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Anti-CD19 iCAR NK Cells | SEP | Phase 1 | NCT03824951 | Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma | UNKNOWN |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||